The PD-1/B7-H1 pathway modulates the natural killer cells versus mouse glioma stem cells.
<h4>Purpose</h4>Glioblastoma multiforme (GBM) is the most malignant primary type of brain tumor in adults. There has been increased focus on the immunotherapies to treat GBM patients, the therapeutic value of natural killer (NK) cells is still unknown. Programmed death-1 (PD-1) is a majo...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2015-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0134715 |
id |
doaj-c97b5587bbf844489dd95526591c9e7c |
---|---|
record_format |
Article |
spelling |
doaj-c97b5587bbf844489dd95526591c9e7c2021-03-04T07:40:01ZengPublic Library of Science (PLoS)PLoS ONE1932-62032015-01-01108e013471510.1371/journal.pone.0134715The PD-1/B7-H1 pathway modulates the natural killer cells versus mouse glioma stem cells.Bo Yuan HuangYi Ping ZhanWen Jing ZongChun Jiang YuJun Fa LiYan Ming QuSong Han<h4>Purpose</h4>Glioblastoma multiforme (GBM) is the most malignant primary type of brain tumor in adults. There has been increased focus on the immunotherapies to treat GBM patients, the therapeutic value of natural killer (NK) cells is still unknown. Programmed death-1 (PD-1) is a major immunological checkpoint that can negatively regulate the T-cell-mediated immune response. We tested the combination of the inhibiting the PD-1/B7H1 pathway with a NK-cell mediated immune response in an orthotopic mouse model of GBM.<h4>Methods and materials</h4>Mouse glioma stem cells (GL261GSCs) and mouse NK cells were isolated and identified. A lactate dehydrogenase (LDH) assay was perfomed to detect the cytotoxicity of NK cells against GL261GSCs. GL261GSCs were intracranially implanted into mice, and the mice were stratified into 3 treatment groups: 1) control, 2) NK cells treatment, and 3) PD-1 inhibited NK cells treatment group. Overall survival was quantified, and animal magnetic resonance imaging (MRI) was performed to determine tumor growth. The brains were harvested after the mice were euthanized, and immunohistochemistry against CD45 and PCNA was performed.<h4>Results</h4>The mouse NK cells were identified as 90% CD3- NK1.1+CD335+ by flow cytometric analysis. In the LDH assay, the ratios of the damaged GL261GSCs, with the E:T ratios of 2.5:1, 5:1, and 10:1, were as follows: 1) non-inhibited group: 7.42%, 11.31%, and 15.1%, 2) B7H1 inhibited group: 14.75%, 18.25% and 29.1%, 3) PD-1 inhibited group: 15.53%, 19.21% and 29.93%, 4) double inhibited group: 33.24%, 42.86% and 54.91%. In the in vivo experiments, the mice in the PD-1 inhibited NK cells treatment group and IL-2-stimulated-NK cells treatment group displayed a slowest tumor growth (F = 308.5, P<0.01) and a slower tumor growth compared with control group (F = 118.9, P<0.01), respectively. The median survival of the mice in the three groups were as follows: 1) conrol group: 29 days, 2) NK cells treatment group: 35 days (P = 0.0012), 3) PD-1 inhibited NK cells treatment group: 44 days (P = 0.0024). Immunologic data of PCNA-positive cell ratios and CD45-positive cell ratios of the tumor specimens in the three groups were as follows: 1) control group: 65.72% (PCNA) and 0.92% (CD45), 2) NK treatment group: 27.66% (PCNA) and 13.46% (CD45), and 3) PD-1 inhibited NK cells treatment group: 13.66% (PCNA) and 23.66% (CD45) (P<0.001).<h4>Conclusion</h4>The results demonstrated that blockade of PD-1/B7H1 pathway could promote mouse NK cells to kill the GL261GSCs, and the PD-1-inhibited NK cells could be a feasible immune therapeutic approach against GBM.https://doi.org/10.1371/journal.pone.0134715 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Bo Yuan Huang Yi Ping Zhan Wen Jing Zong Chun Jiang Yu Jun Fa Li Yan Ming Qu Song Han |
spellingShingle |
Bo Yuan Huang Yi Ping Zhan Wen Jing Zong Chun Jiang Yu Jun Fa Li Yan Ming Qu Song Han The PD-1/B7-H1 pathway modulates the natural killer cells versus mouse glioma stem cells. PLoS ONE |
author_facet |
Bo Yuan Huang Yi Ping Zhan Wen Jing Zong Chun Jiang Yu Jun Fa Li Yan Ming Qu Song Han |
author_sort |
Bo Yuan Huang |
title |
The PD-1/B7-H1 pathway modulates the natural killer cells versus mouse glioma stem cells. |
title_short |
The PD-1/B7-H1 pathway modulates the natural killer cells versus mouse glioma stem cells. |
title_full |
The PD-1/B7-H1 pathway modulates the natural killer cells versus mouse glioma stem cells. |
title_fullStr |
The PD-1/B7-H1 pathway modulates the natural killer cells versus mouse glioma stem cells. |
title_full_unstemmed |
The PD-1/B7-H1 pathway modulates the natural killer cells versus mouse glioma stem cells. |
title_sort |
pd-1/b7-h1 pathway modulates the natural killer cells versus mouse glioma stem cells. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2015-01-01 |
description |
<h4>Purpose</h4>Glioblastoma multiforme (GBM) is the most malignant primary type of brain tumor in adults. There has been increased focus on the immunotherapies to treat GBM patients, the therapeutic value of natural killer (NK) cells is still unknown. Programmed death-1 (PD-1) is a major immunological checkpoint that can negatively regulate the T-cell-mediated immune response. We tested the combination of the inhibiting the PD-1/B7H1 pathway with a NK-cell mediated immune response in an orthotopic mouse model of GBM.<h4>Methods and materials</h4>Mouse glioma stem cells (GL261GSCs) and mouse NK cells were isolated and identified. A lactate dehydrogenase (LDH) assay was perfomed to detect the cytotoxicity of NK cells against GL261GSCs. GL261GSCs were intracranially implanted into mice, and the mice were stratified into 3 treatment groups: 1) control, 2) NK cells treatment, and 3) PD-1 inhibited NK cells treatment group. Overall survival was quantified, and animal magnetic resonance imaging (MRI) was performed to determine tumor growth. The brains were harvested after the mice were euthanized, and immunohistochemistry against CD45 and PCNA was performed.<h4>Results</h4>The mouse NK cells were identified as 90% CD3- NK1.1+CD335+ by flow cytometric analysis. In the LDH assay, the ratios of the damaged GL261GSCs, with the E:T ratios of 2.5:1, 5:1, and 10:1, were as follows: 1) non-inhibited group: 7.42%, 11.31%, and 15.1%, 2) B7H1 inhibited group: 14.75%, 18.25% and 29.1%, 3) PD-1 inhibited group: 15.53%, 19.21% and 29.93%, 4) double inhibited group: 33.24%, 42.86% and 54.91%. In the in vivo experiments, the mice in the PD-1 inhibited NK cells treatment group and IL-2-stimulated-NK cells treatment group displayed a slowest tumor growth (F = 308.5, P<0.01) and a slower tumor growth compared with control group (F = 118.9, P<0.01), respectively. The median survival of the mice in the three groups were as follows: 1) conrol group: 29 days, 2) NK cells treatment group: 35 days (P = 0.0012), 3) PD-1 inhibited NK cells treatment group: 44 days (P = 0.0024). Immunologic data of PCNA-positive cell ratios and CD45-positive cell ratios of the tumor specimens in the three groups were as follows: 1) control group: 65.72% (PCNA) and 0.92% (CD45), 2) NK treatment group: 27.66% (PCNA) and 13.46% (CD45), and 3) PD-1 inhibited NK cells treatment group: 13.66% (PCNA) and 23.66% (CD45) (P<0.001).<h4>Conclusion</h4>The results demonstrated that blockade of PD-1/B7H1 pathway could promote mouse NK cells to kill the GL261GSCs, and the PD-1-inhibited NK cells could be a feasible immune therapeutic approach against GBM. |
url |
https://doi.org/10.1371/journal.pone.0134715 |
work_keys_str_mv |
AT boyuanhuang thepd1b7h1pathwaymodulatesthenaturalkillercellsversusmousegliomastemcells AT yipingzhan thepd1b7h1pathwaymodulatesthenaturalkillercellsversusmousegliomastemcells AT wenjingzong thepd1b7h1pathwaymodulatesthenaturalkillercellsversusmousegliomastemcells AT chunjiangyu thepd1b7h1pathwaymodulatesthenaturalkillercellsversusmousegliomastemcells AT junfali thepd1b7h1pathwaymodulatesthenaturalkillercellsversusmousegliomastemcells AT yanmingqu thepd1b7h1pathwaymodulatesthenaturalkillercellsversusmousegliomastemcells AT songhan thepd1b7h1pathwaymodulatesthenaturalkillercellsversusmousegliomastemcells AT boyuanhuang pd1b7h1pathwaymodulatesthenaturalkillercellsversusmousegliomastemcells AT yipingzhan pd1b7h1pathwaymodulatesthenaturalkillercellsversusmousegliomastemcells AT wenjingzong pd1b7h1pathwaymodulatesthenaturalkillercellsversusmousegliomastemcells AT chunjiangyu pd1b7h1pathwaymodulatesthenaturalkillercellsversusmousegliomastemcells AT junfali pd1b7h1pathwaymodulatesthenaturalkillercellsversusmousegliomastemcells AT yanmingqu pd1b7h1pathwaymodulatesthenaturalkillercellsversusmousegliomastemcells AT songhan pd1b7h1pathwaymodulatesthenaturalkillercellsversusmousegliomastemcells |
_version_ |
1714808205387759616 |